Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 
ORIGINAL ARTICLE
Year : 2014  |  Volume : 10  |  Issue : 7  |  Page : 225-228

Tumor M2-pyruvate kinase in stool as a biomarker for diagnosis of colorectal cancer: A meta-analysis


1 Department of General Surgery, First Affiliated Hospital of Zhengzhou University, Henan Zhengzhou 450052; Department of General Surgery, The Affiliated Cancer Hospital of Zhengzhou University, Henan Zhengzhou 450003, China
2 Department of Anesthesiology, The Affiliated Cancer Hospital of Zhengzhou University, Henan Zhengzhou 450003, China
3 Department of General Surgery, The Affiliated Cancer Hospital of Zhengzhou University, Henan Zhengzhou 450003, China
4 Department of General Surgery, First Affiliated Hospital of Zhengzhou University, Henan Zhengzhou 450052, China

Correspondence Address:
Xie-Fu Zhang
Department of General Surgery, First Affiliated Hospital of Zhengzhou University, Henan Zhengzhou 450052
China
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/0973-1482.145886

Rights and Permissions

Objective: The aim of this meta-analysis was to evaluate the diagnosis value of tumor M2-pyruvate kinase (M2-PK) in stool as a biomarker for diagnosis of colorectal cancer. Materials and Methods: By searching the databases of Cochrane Library, PubMed, China national knowledge Information and Wanfang, the diagnosis study related to tumor M2-PK in stool as a biomarker for diagnosis of colorectal cancer were screened and included in this study. The pooled sensitivity, specificity, positive likelihood ratio (+LR), negative likelihood ratio (−LR) and the receiver operating characteristic curve (ROC) were calculated by stata 11.0 software. Results: According to the including criteria, 14 trials including 1990 subjects were finally included in this meta-analysis. The pooled diagnosis sensitivity, specificity, +LR, −LR and area under curve were 0.78 (95% confidence interval [CI]: 0.74-0.81), 0.77 (95% CI: 0.76-0.79), 4.38 (95% CI: 3.27-5.88), 0.28 (95% CI: 0.23-0.34) and 0.86 (95% CI: 0.834-0.89). No statistical publication bias was found in this study. Conclusion: Tumor M2-PK in stool can be a useful biomarker in the diagnosis of colorectal cancer with relative high sensitivity and specificity.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed1693    
    Printed49    
    Emailed1    
    PDF Downloaded142    
    Comments [Add]    

Recommend this journal